ATE303386T1 - Das citrat-salz des 5,8,14,- triazatetracyclo(10.3.1.02,11.04,9)-hexadeca- 2(11),3,5,7,9-pentaens - Google Patents

Das citrat-salz des 5,8,14,- triazatetracyclo(10.3.1.02,11.04,9)-hexadeca- 2(11),3,5,7,9-pentaens

Info

Publication number
ATE303386T1
ATE303386T1 AT02724553T AT02724553T ATE303386T1 AT E303386 T1 ATE303386 T1 AT E303386T1 AT 02724553 T AT02724553 T AT 02724553T AT 02724553 T AT02724553 T AT 02724553T AT E303386 T1 ATE303386 T1 AT E303386T1
Authority
AT
Austria
Prior art keywords
triazatetracyclo
pentaene
hexadeca
citrate salt
citrate
Prior art date
Application number
AT02724553T
Other languages
German (de)
English (en)
Inventor
Philip James Johnson
Peter Robert Rose
Lewin Theophilus Wint
Glenn Robert Williams
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE303386(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE303386T1 publication Critical patent/ATE303386T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
AT02724553T 2001-05-14 2002-04-26 Das citrat-salz des 5,8,14,- triazatetracyclo(10.3.1.02,11.04,9)-hexadeca- 2(11),3,5,7,9-pentaens ATE303386T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29086301P 2001-05-14 2001-05-14
PCT/IB2002/001450 WO2002092597A1 (en) 2001-05-14 2002-04-26 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ATE303386T1 true ATE303386T1 (de) 2005-09-15

Family

ID=23117854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02724553T ATE303386T1 (de) 2001-05-14 2002-04-26 Das citrat-salz des 5,8,14,- triazatetracyclo(10.3.1.02,11.04,9)-hexadeca- 2(11),3,5,7,9-pentaens

Country Status (37)

Country Link
US (1) US6787549B2 (https=)
EP (1) EP1390366B1 (https=)
JP (1) JP4137645B2 (https=)
KR (1) KR20040008175A (https=)
CN (1) CN1509288A (https=)
AP (1) AP1429A (https=)
AR (1) AR035889A1 (https=)
AT (1) ATE303386T1 (https=)
BG (1) BG108344A (https=)
CA (1) CA2446988A1 (https=)
CZ (1) CZ20032917A3 (https=)
DE (1) DE60205888T2 (https=)
DO (1) DOP2002000390A (https=)
DZ (1) DZ3503A1 (https=)
EA (1) EA005529B1 (https=)
EE (1) EE200300557A (https=)
ES (1) ES2245731T3 (https=)
GT (1) GT200200081A (https=)
HR (1) HRP20030911A2 (https=)
HU (1) HUP0304085A3 (https=)
IL (1) IL157874A0 (https=)
IS (1) IS6956A (https=)
MA (1) MA27021A1 (https=)
MX (1) MXPA03010365A (https=)
MY (1) MY134123A (https=)
NO (1) NO20035035D0 (https=)
NZ (1) NZ528209A (https=)
OA (1) OA12600A (https=)
PA (1) PA8545001A1 (https=)
PE (1) PE20021095A1 (https=)
PL (1) PL366774A1 (https=)
SK (1) SK13372003A3 (https=)
TN (1) TNSN03112A1 (https=)
UA (1) UA73421C2 (https=)
UY (1) UY27287A1 (https=)
WO (1) WO2002092597A1 (https=)
ZA (1) ZA200307234B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839131T3 (de) * 1997-12-31 2015-05-07 Pfizer Products Inc. Arylkondensierte azapolycyclische derivate
ATE356625T1 (de) * 2001-11-30 2007-04-15 Pfizer Prod Inc Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung enthaltend 5,8,14- triazatetracyclo (10.3.1.0(2,11) 0 (4,9) )- hexadeca-2(11) 3, 5,7, 9-pentaene
BRPI0410219A (pt) * 2003-05-20 2006-05-09 Pfizer Prod Inc composições farmacêuticas de vareniclina
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
BRPI0718600A2 (pt) * 2006-11-09 2013-12-10 Pfizer Prod Inc Polimorfos de intermediários nicotínicos.
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
EP2268639A2 (en) 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
NZ593223A (en) * 2008-12-11 2013-08-30 Cell Therapeutics Inc 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8, 12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
CA2801842A1 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
JP5925381B2 (ja) 2012-04-13 2016-05-25 ▲連雲▼港金康和信▲薬業▼有限公司Ｌｉａｎｙｕｎｇａｎｇ Ｊｉｎｋａｎｇ Ｈｅｘｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 化合物［４−（２−アミノ−１０−メチル−４−オキソ−６，７，８，９−テトラヒドロ−４ａ，７−エピミノピリミド［４，５−ｂ］［１，４］ジアゼピン−５（４Ｈ）−イル）ベンゾイル］−グルタメート及びその製造
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) * 2019-06-28 2020-12-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Microparticulate varenicline citrate
WO2021188563A1 (en) * 2020-03-16 2021-09-23 Chengdu Scimount Pharmatech Co., Ltd. 5-ht3 receptor modulator, the crystalline form, methods of making, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839131T3 (de) * 1997-12-31 2015-05-07 Pfizer Products Inc. Arylkondensierte azapolycyclische derivate
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
DE60205888D1 (de) 2005-10-06
DZ3503A1 (https=) 2002-11-21
KR20040008175A (ko) 2004-01-28
US20030149091A1 (en) 2003-08-07
EP1390366A1 (en) 2004-02-25
TNSN03112A1 (fr) 2005-12-23
IL157874A0 (en) 2004-03-28
DE60205888T2 (de) 2006-07-06
AR035889A1 (es) 2004-07-21
EE200300557A (et) 2004-04-15
MA27021A1 (fr) 2004-12-20
AP2002002522A0 (en) 2002-06-30
UY27287A1 (es) 2003-02-28
UA73421C2 (en) 2005-07-15
OA12600A (en) 2006-06-09
PA8545001A1 (es) 2003-09-05
NZ528209A (en) 2004-09-24
CZ20032917A3 (cs) 2004-07-14
CA2446988A1 (en) 2002-11-21
GT200200081A (es) 2003-04-22
DOP2002000390A (es) 2003-03-15
PL366774A1 (en) 2005-02-07
US6787549B2 (en) 2004-09-07
EA005529B1 (ru) 2005-04-28
HUP0304085A2 (en) 2004-04-28
ZA200307234B (en) 2004-09-16
MY134123A (en) 2007-11-30
EA200301120A1 (ru) 2004-02-26
HRP20030911A2 (en) 2004-02-29
CN1509288A (zh) 2004-06-30
EP1390366B1 (en) 2005-08-31
HUP0304085A3 (en) 2005-09-28
JP4137645B2 (ja) 2008-08-20
MXPA03010365A (es) 2004-03-16
ES2245731T3 (es) 2006-01-16
AP1429A (en) 2005-06-13
PE20021095A1 (es) 2002-12-14
BG108344A (bg) 2004-12-30
IS6956A (is) 2003-09-15
NO20035035L (no) 2003-11-13
JP2004529186A (ja) 2004-09-24
WO2002092597A1 (en) 2002-11-21
NO20035035D0 (no) 2003-11-13
SK13372003A3 (sk) 2004-08-03

Similar Documents

Publication Publication Date Title
DE60205742D1 (de) Tartrate des 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaens
DE60205888D1 (de) Das citrat-salz des 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaens
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
BR0216099B1 (pt) "conjunto de desgaste".
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
DE60236367D1 (de) Echolöscher, der eine weitere reduktion des restechos sicherstellt
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
EG23429A (en) Novel a-oxygenated or a-thiolated carboxylic acid phenethylamide derivatives.
RU2000118409A (ru) Антимутагенное средство
IT1320082B1 (it) Procedimento per la realizzazione di reggiseni, nonche' reggisenocosi' ottenuto.
IT1318986B1 (it) Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
ATE470655T1 (de) Substituierte 1,5-diaminopentan-3-ol-verbindungen
Edbom Jouren-livsviktig fraga
ITMO20020019V0 (it) ,,utensile da cucina per l'essicazione di alimenti,,.
ITMI20011344A0 (it) Procedimento per la preparazione di 1,3-diossolan-2-oni
EG23305A (en) Preparation of 1,2-dicloroethane.
UA5878S (uk) Жниварка валкова причіпна жвп - 4,9
ES1048424Y (es) Colgador perfeccionado.
ES1050049Y (es) Prenda de vestir perfeccionada.
ITMI20001600A1 (it) Procedimento per la preparazione di 5-amino-4-alo-3-alchil isossazoli.
IS7299A (is) 3,4-díhýdró-1H-ísókínólóín-2-ýl-afleiður
ITTO20000397A0 (it) Procedimento perfezionato per la preparazione di 4-alchil-3-alcossianiline.
ITUD20030211A1 (it) Procedimento per la realizzazione di un'impugnatura di un ferro da stiro, e impugnatura realizzata mediante tale procedimento.
DK1173092T3 (da) Pulssensor
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties